Equities researchers at Stifel Nicolaus lifted their price objective on shares of Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) from $85.00 to $100.00 in a research report issued on Wednesday, Analyst Ratings Network.com reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ target price would suggest a potential upside of 6.63% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Cantor Fitzgerald raised their price target on shares of Jazz Pharmaceuticals Plc from $97.00 to $106.00 in a research note to investors on Wednesday. They now have a “buy” rating on the stock. Separately, analysts at Brean Capital raised their price target on shares of Jazz Pharmaceuticals Plc from $93.00 to $119.00 in a research note to investors on Wednesday. They now have a “buy” rating on the stock. Finally, analysts at UBS AG raised their price target on shares of Jazz Pharmaceuticals Plc from $98.00 to $110.00 in a research note to investors on Wednesday. They now have a “buy” rating on the stock. One investment analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $93.47.
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) traded up 1.25% on Wednesday, hitting $93.78. The stock had a trading volume of 1,149,856 shares. Jazz Pharmaceuticals Plc has a 52 week low of $47.37 and a 52 week high of $95.24. The stock’s 50-day moving average is $88.71 and its 200-day moving average is $75.93. The company has a market cap of $5.454 billion and a price-to-earnings ratio of 17.76.
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.11. The company had revenue of $232.20 million for the quarter, compared to the consensus estimate of $227.38 million. During the same quarter in the prior year, the company posted $1.29 earnings per share. The company’s quarterly revenue was up 32.3% on a year-over-year basis. Analysts expect that Jazz Pharmaceuticals Plc will post $6.30 EPS for the current fiscal year.
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.